Dividend growth investing builds long-term wealth for retirement by focusing on companies that consistently increase payouts.

The U.S. Food and Drug Administration approved Novo Nordisk's weight-loss pill on Monday, giving the Danish drugmaker a leg ...

Novo Nordisk gained a head start in the GLP-1 race but then fell behind; Pfizer is working hard to catch up to the new leader ...

The U.S. Food and Drug Administration on Dec. 22 approved a pill version of Novo Nordisk’s weight-loss drug Wegovy.

The U.S. Food and Drug Administration's approval of an oral version of Novo Nordisk's weight-loss drug Wegovy could ...

Monday’s approval gives Novo Nordisk a win against GLP-1 competitor Eli Lilly, which manufactures a weight loss injectable ...

Eli Lilly stock fell on Tuesday after Novo Nordisk, its rival in diabetes and weight-loss drugs, secured regulatory approval ...

Novo Nordisk shares climbed after U.S. regulators approved a tablet version of Ozempic and Wegovy, paving the way for the ...

Novo Nordisk’s oral Wegovy wins FDA approval, outperforming rivals in weight loss. Discover why NVO stock is undervalued now.

Novo Nordisk (NVO) stock gains as the FDA approves the company's Wegovy pill, as Eli Lilly (LLY) awaits FDA review for its ...

But Eli Lilly's Zepbound is best in class. Zepbound caused greater average weight loss than Wegovy in a head-to-head study. And through the first nine months of 2025, Zepbound generated $9.3 billion ...

The pharmaceutical giant's stock has tumbled over the past year and a half, but it could be poised to storm back.